Analysts Expect Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share

Analysts expect Cascadian Therapeutics Inc (NASDAQ:CASC) to report earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics posted earnings per share of ($0.47) during the same quarter last year, which indicates a positive year over year growth rate of 38.3%. The company is expected to announce its next earnings report on Thursday, March 8th.

On average, analysts expect that Cascadian Therapeutics will report full year earnings of ($1.27) per share for the current year, with EPS estimates ranging from ($1.53) to ($1.14). For the next financial year, analysts expect that the firm will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Cascadian Therapeutics.

A number of brokerages have recently commented on CASC. ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 31st. Zacks Investment Research raised shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Monday, November 13th. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Finally, Raymond James Financial cut shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $5.63.

Shares of Cascadian Therapeutics (NASDAQ CASC) traded down $0.01 during trading hours on Tuesday, hitting $9.98. 807,900 shares of the stock were exchanged, compared to its average volume of 1,405,221. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.21. The stock has a market capitalization of $505.68, a PE ratio of -7.39 and a beta of 3.96.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund purchased a new position in Cascadian Therapeutics during the second quarter worth about $136,000. Rhumbline Advisers purchased a new position in Cascadian Therapeutics during the second quarter worth about $143,000. SG Americas Securities LLC raised its holdings in Cascadian Therapeutics by 194.7% during the fourth quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 25,464 shares in the last quarter. Alps Advisors Inc. purchased a new position in Cascadian Therapeutics during the fourth quarter worth about $207,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in Cascadian Therapeutics during the second quarter worth about $225,000. 80.59% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/13/analysts-expect-cascadian-therapeutics-inc-casc-will-post-earnings-of-0-29-per-share.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply